WO2011016026A3 - Novel proteins - Google Patents

Novel proteins Download PDF

Info

Publication number
WO2011016026A3
WO2011016026A3 PCT/IL2010/000621 IL2010000621W WO2011016026A3 WO 2011016026 A3 WO2011016026 A3 WO 2011016026A3 IL 2010000621 W IL2010000621 W IL 2010000621W WO 2011016026 A3 WO2011016026 A3 WO 2011016026A3
Authority
WO
WIPO (PCT)
Prior art keywords
prt8
prt6
prt7
polypeptides
involved
Prior art date
Application number
PCT/IL2010/000621
Other languages
French (fr)
Other versions
WO2011016026A2 (en
Inventor
Tamara Sandler
Orly Devary
Original Assignee
Two To Biotech Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US13/387,392 priority Critical patent/US8647632B2/en
Priority to SG2012005070A priority patent/SG178097A1/en
Priority to EP10806144.1A priority patent/EP2461829B1/en
Priority to CA2769001A priority patent/CA2769001C/en
Application filed by Two To Biotech Ltd. filed Critical Two To Biotech Ltd.
Priority to CN201080044688.3A priority patent/CN102596247B/en
Priority to JP2012523432A priority patent/JP2013500739A/en
Priority to AU2010280368A priority patent/AU2010280368B2/en
Priority to IN879DEN2012 priority patent/IN2012DN00879A/en
Publication of WO2011016026A2 publication Critical patent/WO2011016026A2/en
Publication of WO2011016026A3 publication Critical patent/WO2011016026A3/en
Priority to IL217758A priority patent/IL217758A/en
Priority to HK12112520.0A priority patent/HK1171672A1/en
Priority to US14/146,237 priority patent/US9296786B2/en
Priority to IL240134A priority patent/IL240134A/en
Priority to US14/953,759 priority patent/US20160083445A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Provided herein are four polypeptides, named PRT5, PRT6, PRT7 and PRT8, the nucleic acids encoding the same, compositions comprising the proteins, as well as their uses in therapeutic and diagnostic methods. Antibodies which specifically recognize the polypeptides are also provided, as well as their uses. Characterization of each protein showed that PRT5 and PRT8 are involved in glucose metabolism, PRT6 is involved in androgen regulation, while PRT7 correlates with cancer.
PCT/IL2010/000621 2009-08-02 2010-08-02 Novel proteins WO2011016026A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP2012523432A JP2013500739A (en) 2009-08-02 2010-08-02 New protein
EP10806144.1A EP2461829B1 (en) 2009-08-02 2010-08-02 Novel proteins
CA2769001A CA2769001C (en) 2009-08-02 2010-08-02 Chemokine-like secreted proteins involved in glucose metabolism
IN879DEN2012 IN2012DN00879A (en) 2009-08-02 2010-08-02
CN201080044688.3A CN102596247B (en) 2009-08-02 2010-08-02 Novel proteins
SG2012005070A SG178097A1 (en) 2009-08-02 2010-08-02 Novel proteins
AU2010280368A AU2010280368B2 (en) 2009-08-02 2010-08-02 Novel proteins
US13/387,392 US8647632B2 (en) 2009-08-02 2010-08-02 Proteins
IL217758A IL217758A (en) 2009-08-02 2012-01-26 Polypeptides enhancing glucose metabolism, nucleic acid molecules encoding the same, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments
HK12112520.0A HK1171672A1 (en) 2009-08-02 2012-12-05 Novel proteins
US14/146,237 US9296786B2 (en) 2009-08-02 2014-01-02 Shortened secreted polypeptides
IL240134A IL240134A (en) 2009-08-02 2015-07-23 Polypeptides enhancing testosterone production, nucleic acid molecules encoding the same, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments
US14/953,759 US20160083445A1 (en) 2009-08-02 2015-11-30 Novel polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL200202 2009-08-02
IL200202A IL200202A0 (en) 2009-08-02 2009-08-02 Novel proteins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/387,392 A-371-Of-International US8647632B2 (en) 2009-08-02 2010-08-02 Proteins
US14/146,237 Continuation-In-Part US9296786B2 (en) 2009-08-02 2014-01-02 Shortened secreted polypeptides

Publications (2)

Publication Number Publication Date
WO2011016026A2 WO2011016026A2 (en) 2011-02-10
WO2011016026A3 true WO2011016026A3 (en) 2011-05-26

Family

ID=42263570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2010/000621 WO2011016026A2 (en) 2009-08-02 2010-08-02 Novel proteins

Country Status (12)

Country Link
US (1) US8647632B2 (en)
EP (2) EP2461829B1 (en)
JP (3) JP2013500739A (en)
KR (1) KR101623355B1 (en)
CN (1) CN102596247B (en)
AU (1) AU2010280368B2 (en)
CA (1) CA2769001C (en)
HK (1) HK1171672A1 (en)
IL (3) IL200202A0 (en)
IN (1) IN2012DN00879A (en)
SG (2) SG178097A1 (en)
WO (1) WO2011016026A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140155324A1 (en) * 2011-08-08 2014-06-05 Two To Biotech Ltd. Novel peptides and uses thereof in therapeutic methods
AU2014374945A1 (en) * 2014-01-02 2016-07-21 Two To Biotech Ltd. Novel polypeptides
CN104262468B (en) * 2014-09-28 2017-01-18 新乡医学院 Glucose transporter inhibiting polypeptide as well as preparation method and application thereof
CN107548404B (en) 2015-03-05 2021-05-07 积水精细化工美国有限公司 PVOH dispersants for VCM polymerization
KR20240005121A (en) 2015-12-11 2024-01-11 고쿠리츠다이가쿠호진 고치다이가쿠 Marker for pancreatic cancer and intraductal papillary mucinous tumors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020114779A1 (en) * 2000-06-19 2002-08-22 Williams John P. Osteoclast secreted chemokine and uses thereof
US20060269921A1 (en) * 2003-02-18 2006-11-30 Davendra Segara Methods of diagnosis and prognosis of pancreatic cancer
US20070020624A1 (en) * 1998-02-18 2007-01-25 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Pseudomonas aeruginosa for diagnostics and therapeutics
US20080206231A1 (en) * 2004-10-05 2008-08-28 Oregon Health And Science University Compositions and Methods for Treating Disease
US20080248134A1 (en) * 2005-05-04 2008-10-09 Auckland Uniservices Limited Oral compositions, use and combinations of N-[2-(dimethylamino)ethyl]-2,6 dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide and closely related analogues thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5286846A (en) 1991-06-14 1994-02-15 The Government Of The United States Of America As Represented By The Dept. Of Health And Human Services Amino acid derivative and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides
WO2001087316A2 (en) * 2000-05-15 2001-11-22 Braswell, Glenn, A. Composition and method for increasing testosterone levels
EP2097538A4 (en) * 2006-12-07 2011-11-30 Switchgear Genomics Transcriptional regulatory elements of biological pathways, tools, and methods

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020624A1 (en) * 1998-02-18 2007-01-25 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Pseudomonas aeruginosa for diagnostics and therapeutics
US20020114779A1 (en) * 2000-06-19 2002-08-22 Williams John P. Osteoclast secreted chemokine and uses thereof
US20060269921A1 (en) * 2003-02-18 2006-11-30 Davendra Segara Methods of diagnosis and prognosis of pancreatic cancer
US20080206231A1 (en) * 2004-10-05 2008-08-28 Oregon Health And Science University Compositions and Methods for Treating Disease
US20080248134A1 (en) * 2005-05-04 2008-10-09 Auckland Uniservices Limited Oral compositions, use and combinations of N-[2-(dimethylamino)ethyl]-2,6 dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide and closely related analogues thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE UNIPROTKB/TREMBL [online] 15 January 2008 (2008-01-15), FRANGEUL.: "Similarity to trQODG52QODG52_ORYSA Os05g0552600 Protein (Fragment).", XP008150817, Database accession no. A8YAX1 *
DATABASE UNIPROTKB/TREMBL [online] 24 January 2006 (2006-01-24), CARNINCI ET AL.: "RCB-1283 B16 Melanoma cDNA, RIKEN Full-Length Enriched Library.", XP008150821, Database accession no. Q3TMX7 *
DATABASE UNIPROTKB/TREMBL [online] 4 December 2007 (2007-12-04), COPELAND ET AL.: "Putative Uncharacterized Protein Precursor.", XP008150822, Database accession no. A8M957 *

Also Published As

Publication number Publication date
SG10201404735VA (en) 2014-10-30
IL217758A (en) 2015-10-29
CN102596247B (en) 2014-08-06
EP2985035A1 (en) 2016-02-17
WO2011016026A2 (en) 2011-02-10
JP2013500739A (en) 2013-01-10
US20120121602A1 (en) 2012-05-17
US8647632B2 (en) 2014-02-11
IL217758A0 (en) 2012-03-29
JP2015157811A (en) 2015-09-03
KR20120063474A (en) 2012-06-15
EP2461829A4 (en) 2013-06-19
CN102596247A (en) 2012-07-18
AU2010280368B2 (en) 2015-07-23
AU2010280368A1 (en) 2012-03-15
EP2461829A2 (en) 2012-06-13
IN2012DN00879A (en) 2015-07-10
HK1171672A1 (en) 2013-04-05
EP2461829B1 (en) 2016-01-06
KR101623355B1 (en) 2016-05-23
IL200202A0 (en) 2010-05-31
CA2769001A1 (en) 2011-02-10
IL240134A (en) 2016-07-31
CA2769001C (en) 2016-07-26
JP5833780B2 (en) 2015-12-16
IL240134A0 (en) 2015-09-24
SG178097A1 (en) 2012-03-29
JP2015212302A (en) 2015-11-26

Similar Documents

Publication Publication Date Title
TN2012000167A1 (en) Human il-23 antigen binding proteins
CA2851316C (en) Genes and proteins for alkanoyl-coa synthesis
WO2010120514A3 (en) Antigen-binding proteins comprising recombinant protein scaffolds
WO2014106015A3 (en) Multivalent binding protein compositions
WO2013151736A3 (en) In vivo production of proteins
WO2011139986A3 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
HK1215954A1 (en) Btnl9 proteins, nucleic acids, and antibodies and uses thereof btnl9
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
WO2008101985A3 (en) Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
EP4050027A3 (en) Cx3cr1-binding polypeptides
WO2011139714A3 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
WO2011140132A3 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
WO2011143482A3 (en) Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
WO2011084808A3 (en) Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
MX353813B (en) Vegf-binding molecules.
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
WO2008104890A3 (en) Compositions and methods for producing apolipoprotein
WO2013045707A3 (en) Biological materials related to c-met
WO2011016026A3 (en) Novel proteins
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
WO2012122378A3 (en) Antibody-like proteins for therapeutic and diagnostic use
WO2011085134A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
WO2011005523A3 (en) Galectin-immunoglobulin chimeric molecules
WO2007089923A3 (en) Modifications of cst-ii for increased protein expression
WO2010041145A3 (en) Il-17-mediated transfection methods

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080044688.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10806144

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2769001

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 217758

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 13387392

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 879/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2012523432

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010806144

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20127004449

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010280368

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2010280368

Country of ref document: AU

Date of ref document: 20100802

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 240134

Country of ref document: IL